STUDY OBJECTIVES: To measure the quality of secondary prevention of stroke provided to patients in England, Wales and Northern Ireland. DESIGN: Retrospective case note analysis. SETTING: 235 hospitals (95% of all such hospitals), providing care for acute stroke patients in England, Wales and Northern Ireland and primary health care for follow-up data. PATIENTS: 8,200 patients admitted with stroke between 1(st) April and 30(th) June 2001. Data on up to 40 consecutive cases submitted by each hospital. AUDIT TOOL: Royal College of Physicians Intercollegiate Stroke Working Party Stroke Audit. RESULTS: 24% of patients with previous cerebrovascular disease were not on anti-thrombotic medication at the time of admission. Nine percent of appropriate patients were not taking anti-thrombotic medication at discharge. Patients left with moderate to very severe disability (Barthel scores 14 or less) compared with those independent with mild disability (Barthel score 15-20) were more likely not to have anti-thrombotic treatment (18% versus 8%). Fifty-four percent of patients with known hyperlipidaemia and 21% of those with previous ischaemic heart disease were on lipid lowering therapy on admission. Sixty-four percent of patients had lipids measured during their hospital stay and of those with high total cholesterol or LDL the rate of non-treatment was 36%. Older patients (75+ years) were less likely to be treated (54%) than those <65 years (71%). Seventy-nine percent of known patients with hypertension were on treatment at admission, with 78% being treated by discharge from hospital. At 6 months after stroke a systolic blood pressure of 140 mmHg or less, and a diastolic of 85 mmHg or less, was achieved in 41% of known pre-stroke hypertensives on treatment, 31% of previously untreated hyper-tensives but on treatment at follow-up and 40% of patients not previously labelled as hypertensive. CONCLUSIONS: Major deficiencies in delivery of secondary prevention after stroke have been demonstrated. Services need reorganisation to prevent unnecessary mortality and morbidity in this group of patients.
STUDY OBJECTIVES: To measure the quality of secondary prevention of stroke provided to patients in England, Wales and Northern Ireland. DESIGN: Retrospective case note analysis. SETTING: 235 hospitals (95% of all such hospitals), providing care for acute strokepatients in England, Wales and Northern Ireland and primary health care for follow-up data. PATIENTS: 8,200 patients admitted with stroke between 1(st) April and 30(th) June 2001. Data on up to 40 consecutive cases submitted by each hospital. AUDIT TOOL: Royal College of Physicians Intercollegiate Stroke Working Party Stroke Audit. RESULTS: 24% of patients with previous cerebrovascular disease were not on anti-thrombotic medication at the time of admission. Nine percent of appropriate patients were not taking anti-thrombotic medication at discharge. Patients left with moderate to very severe disability (Barthel scores 14 or less) compared with those independent with mild disability (Barthel score 15-20) were more likely not to have anti-thrombotic treatment (18% versus 8%). Fifty-four percent of patients with known hyperlipidaemia and 21% of those with previous ischaemic heart disease were on lipid lowering therapy on admission. Sixty-four percent of patients had lipids measured during their hospital stay and of those with high total cholesterol or LDL the rate of non-treatment was 36%. Older patients (75+ years) were less likely to be treated (54%) than those <65 years (71%). Seventy-nine percent of known patients with hypertension were on treatment at admission, with 78% being treated by discharge from hospital. At 6 months after stroke a systolic blood pressure of 140 mmHg or less, and a diastolic of 85 mmHg or less, was achieved in 41% of known pre-stroke hypertensives on treatment, 31% of previously untreated hyper-tensives but on treatment at follow-up and 40% of patients not previously labelled as hypertensive. CONCLUSIONS: Major deficiencies in delivery of secondary prevention after stroke have been demonstrated. Services need reorganisation to prevent unnecessary mortality and morbidity in this group of patients.
Authors: Fred Stephen Sarfo; Gloria Kyem; Bruce Ovbiagele; John Akassi; Osei Sarfo-Kantanka; Martin Agyei; Elizabeth Badu; Nathaniel Adusei Mensah Journal: J Stroke Cerebrovasc Dis Date: 2016-09-14 Impact factor: 2.136
Authors: Christianne L Roumie; Alan J Zillich; Dawn M Bravata; Heather A Jaynes; Laura J Myers; Joseph Yoder; Eric M Cheng Journal: Stroke Date: 2014-12-30 Impact factor: 7.914
Authors: Christianne L Roumie; Susan Ofner; Joseph S Ross; Greg Arling; Linda S Williams; Diana L Ordin; Dawn M Bravata Journal: Circ Cardiovasc Qual Outcomes Date: 2011-06-21
Authors: Alex Dregan; Michael A Toschke; Charles D Wolfe; Anthony Rudd; Mark Ashworth; Martin C Gulliford Journal: BMC Public Health Date: 2011-02-07 Impact factor: 3.295
Authors: Phyo K Myint; John F Potter; Gill M Price; Garry R Barton; Anthony K Metcalf; Rachel Hale; Genevieve Dalton; Stanley D Musgrave; Abraham George; Raj Shekhar; Peter Owusu-Agyei; Kevin Walsh; Joseph Ngeh; Anne Nicholson; Diana J Day; Elizabeth A Warburton; Max O Bachmann Journal: BMC Health Serv Res Date: 2011-02-28 Impact factor: 2.655
Authors: Sheena E Ramsay; Peter H Whincup; S G Wannamethee; Olia Papacosta; Lucy Lennon; Mary C Thomas; Richard W Morris Journal: J Public Health (Oxf) Date: 2007-06-21 Impact factor: 2.341
Authors: Alex Dregan; Tjeerd van Staa; Lisa McDermott; Gerard McCann; Mark Ashworth; Judith Charlton; Charles Wolfe; Anthony Rudd; Lucy Yardley; Martin Gulliford Journal: Trials Date: 2012-10-03 Impact factor: 2.279